Cite
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
MLA
Bonaca, Marc P., et al. “Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.” Circulation, vol. 142, no. 8, Aug. 2020, pp. 734–47. EBSCOhost, https://doi.org/10.1161/CIRCULATIONAHA.119.044775.
APA
Bonaca, M. P., Wiviott, S. D., Zelniker, T. A., Mosenzon, O., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Goodrich, E. L., De Mendonca Furtado, R. H., Wilding, J. P. H., Cahn, A., Gause-Nilsson, I. A. M., Johanson, P., Fredriksson, M., Johansson, P. A., Langkilde, A. M., Raz, I., Sabatine, M. S., & Furtado, R. H. D. M. (2020). Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation, 142(8), 734–747. https://doi.org/10.1161/CIRCULATIONAHA.119.044775
Chicago
Bonaca, Marc P., Stephen D. Wiviott, Thomas A. Zelniker, Ofri Mosenzon, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, et al. 2020. “Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.” Circulation 142 (8): 734–47. doi:10.1161/CIRCULATIONAHA.119.044775.